COVID-19 Research

Clinical trial focuses on reducing overactive immune response in COVID-19

View Content

Researchers at Washington University School of Medicine in St. Louis are investigating whether a drug approved by the Food and Drug Administration (FDA) to treat rare diseases of an overactive immune system could help critically ill patients hospitalized with COVID-19. The drug blocks a specific protein of the immune system that doctors suspect contributes to dangerous responses triggered by coronavirus infection in the lungs, kidneys and blood vessels.